Kılıçay, EbruKarahaliloğlu, ZeynepHazer, BakiTekin, İshak ÖzelDenkbaş, Emir Baki13.07.20192019-07-2913.07.20192019-07-2920160265-20481464-5246https://doi.org/10.3109/02652048.2016.1169325https://hdl.handle.net/20.500.12451/5973The aim of this study was to evaluate therapeutic potential of curcumin-loaded poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) PHBHHx nanoparticles (CUR-NPs) and concanavaline A conjugated curcumin-loaded NPs (ConA-CUR-NPs) for breast cancer treatment. The size and zeta potential of prepared NPs were about 228 +/- 5nm and -23.3mV, respectively. The entrapment efficiencies of polymer/drug weight ratios, 1.25CUR-NPs, 2.5CUR-NPs, 5CUR-NPs, ConA-1.25CUR-NPs, ConA-2.5CUR-NPs and ConA-5CUR-NPs were found to be approximate to 68, 55, 45, 70, 60 and 51%, respectively. Optimized NPs formulations in the freeze-dried form were assessed with their short-term stability for 30 days of storage at 4 degrees C and 25 degrees C. Anticancer activity of ConA-CUR-NPs was proved by MTT assay and reconfirmed by double staining and flow cytometry results. The anticancer activity of ConA-CUR-NPs was measured in human breast cancer cells (MDA-MB 231) in vitro, and the results revealed that the ConA-CUR-NPs had better tumor cells decline activity.eninfo:eu-repo/semantics/closedAccessPHBHHxPHBHHx NanoparticlesCurcuminConcanavaline ADrug DeliveryHuman Breast Cancer CellsArticle33327428510.3109/02652048.2016.116932527049468Q2WOS:000376996300009N/A